A preliminary investigation of varenicline for heavy drinking smokers. - Wikidata - awgldk - TriplyDB

A preliminary investigation of varenicline for heavy drinking smokers.

A preliminary investigation of varenicline for heavy drinking smokers.

http://www.wikidata.org/entity/Q36821304

about

Nicotine receptor partial agonists for smoking cessation Nicotine receptor partial agonists for smoking cessation Medications for unhealthy alcohol use: across the spectrum.A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements.Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice."Killing Two Birds with One Stone": Alcohol Use Reduction Interventions with Potential Efficacy in Enhancing Self-Control.The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Varenicline for tobacco dependence: panacea or plight?Varenicline decreases alcohol consumption in heavy-drinking smokers.Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence.Nicotine infusion in the wake-promoting basal forebrain enhances alcohol-induced activation of nucleus accumbens.Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization.Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.Varenicline in the treatment of alcohol use disorders.Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.The role of varenicline on alcohol-primed self-administration and seeking behavior in rats Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis.Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review.Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Pharmacotherapy for alcohol use disorder: current and emerging therapies Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers.Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings.The effects of varenicline on alcohol seeking and self-administration in baboons.Association of the CHRNA4 neuronal nicotinic receptor subunit gene with frequency of binge drinking in young adults.Pharmacological approaches to reducing craving in patients with alcohol use disorders.Nicotine administration in the cholinergic basal forebrain increases alcohol consumption in C57BL/6J mice.Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?Current pharmacological treatment approaches for alcohol dependence.Subjective Response to Alcohol as a Research Domain Criterion.Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

P2860

Q24185773-349A9EEA-0B66-4EED-9E0B-F7BFD5B24BE5 Q24200322-37039E6D-DBD4-4851-AC71-664CF63F74A3 Q27690692-9775DF05-5CE7-4DE9-856A-E11033A736FD Q30412161-2E4D1BBD-BC59-4270-A1F9-777AD962F447 Q30441131-4C38ACB9-C8BF-4AC9-88E3-081748E2DA7B Q30454909-E49006AB-9058-4107-BF50-1A2F1B30BFE1 Q33582051-FFE0D53C-1EE6-4765-89BC-A5B5487EA91E Q33720707-856B515E-1E56-4411-9DDD-EFE729692BF4 Q33943158-82985B6D-D7C9-4F19-824C-34B1303B4BBE Q34097966-E8086FD7-D950-42F9-8D84-60CD7DBDE806 Q34167551-15DDF4C1-207D-4A3B-B459-18DF3F7EA60F Q34190097-98BE830B-21BC-4AA4-8AFD-F25450247011 Q34271996-A20F85B4-64A0-4D03-AAD1-ADBABA2F5EF0 Q34342747-632B39E8-018A-4802-8928-E2897E0887D2 Q34415917-57A4BC44-652D-4E81-85CA-948D11A4C52D Q34940888-30942461-2A23-4710-84ED-5DBA672FC2B3 Q35034473-B23A330B-EE8F-485D-B820-1E00FB8EFA84 Q35195302-B80EDC16-95D7-4DF6-8B5B-09F03B2FC9EE Q35219810-F39349EC-CFCF-41D1-90F0-4B6EC11AAB9E Q35689017-9AA920D4-1CEA-4447-833D-B0A5139DD7AF Q35788371-8FCDEF7B-754F-4BDC-B199-3E9DE62248D0 Q35911952-4B3F6149-705A-4386-BEC4-1AFED3DF6706 Q36039402-9FE0F9E0-624B-4D14-A8AD-64B6DC111975 Q36133717-7A5B9CF2-A915-4211-A145-826DB0E92FE8 Q36231851-63FBDDDD-F386-4548-8F7F-73BF4DB6586B Q36294656-4D87947D-39CA-4796-9401-9FFDACC67335 Q36372867-E3F43FA2-0806-4C12-B815-7740EAE3355C Q36684437-D441819C-7E65-405C-A7DF-3A74CA708E4D Q36724460-33F94566-75AA-41BA-93C9-AEF743F9B952 Q36821822-9100AEDA-6258-40A7-B9DF-CB0D5525E19D Q36877440-A922EAE2-3BAB-4403-AC76-975DC674555E Q37059266-B079B22E-4E53-44B2-A51D-917AE05E404E Q37404736-CE5FC4DF-BCE2-4558-9D11-3A191A042B71 Q37698964-72924E71-4F07-492B-8930-A6C4C1767D37 Q37708082-859F50CB-27E0-442E-9A00-243D9A0A7638 Q37722622-4A0D66CD-43D5-43AB-B1E5-5EEB14677FC2 Q38129470-C291B0F0-F6A0-4C35-BCBC-B01C0507431A Q38181213-01AECC7F-261A-45B8-94B7-583C3DF340FC Q38685941-481096BB-F14B-4F1C-92E0-3F4641072408 Q38718932-3484118D-9A81-4635-8C37-F880E2F8CAA7

P2860

A preliminary investigation of varenicline for heavy drinking smokers.

http://www.wikidata.org/entity/Q36821304

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

A preliminary investigation of varenicline for heavy drinking smokers.

@en

type

label

A preliminary investigation of varenicline for heavy drinking smokers.

@en

prefLabel

A preliminary investigation of varenicline for heavy drinking smokers.

@en

P1433

Q36821304-3EB117B7-45FE-4CC8-812F-784157D48CC7

P1476

Q36821304-1D8E4C4A-B36D-4185-867E-3A43CFA2DEFE

P2093

Q36821304-04019E2B-EA9A-4111-9333-A4D3889B266F

Q36821304-26E6AB78-8AD3-465C-94B9-85FFC61063EC

Q36821304-D6EE271A-7333-4ACA-A4CC-12B9FD1A2074

Q36821304-DA290011-02C3-42E7-8722-E2AC1FA9F172

Q36821304-E1DDF724-1107-4D14-9A70-35E8541E361E

Q36821304-FC6B5182-8A3C-4C11-AD6E-2119F47C8F4B

P2860

Q36821304-023A29D7-8E44-453E-A832-D05AACF3C5F1

Q36821304-04B95B83-0F0B-438F-BF69-031C4B676ABC

Q36821304-0E4105EB-7D3E-4EB1-80D8-AA945557EB5F

Q36821304-10A625A8-0A0E-468F-A8F2-05DC3F692B64

Q36821304-17FC4995-9ECC-4B05-91BF-609B1831EE1B

Q36821304-1FBB05D4-931F-4E67-BF25-B6CC4ACA32D5

Q36821304-216BAFDA-6345-4AB1-8D3E-4786C870D6CE

Q36821304-250DF80E-6641-4459-94B1-1910D524DDB2

Q36821304-25D54C35-D3E3-41D4-B7E8-CF5BA5B17ED3

Q36821304-2CA24CF9-8BD0-49E0-BB03-1542ABB80F8E

P2888

Q36821304-AE44566F-E143-497D-9C66-E4840640A015

P304

Q36821304-0DCEF6D0-BF82-46A7-92B0-B1C202063D61

P31

Q36821304-E79496DA-8E4A-4F98-BAB4-A1907FC0AA0D

P356

Q36821304-EFF64F10-C82C-4D13-94AA-3BF198D26B8A

P433

Q36821304-23EFC9FE-64AA-4FFB-96D8-E48C21CCB0E0

P478

Q36821304-AF12ADE6-1D18-49CB-A5C2-F593B11ED471

P577

Q36821304-521A02D4-DB88-4188-B939-AFD970480B80

P5875

Q36821304-85B50664-DD03-4D22-9795-2805B9BC1CA0

P698

Q36821304-32EA50D0-92DA-4BE9-9025-A92040BC0FD4

P932

Q36821304-11B844A4-0600-4963-9F72-06356867D631

P356

S00213-010-2160-9

P1433

Psychopharmacology

P1476

A preliminary investigation of varenicline for heavy drinking smokers.

@en

P2093

Benjamin A Toll

http://www.w3.org/2001/XMLSchema#string

Denise M Romano

http://www.w3.org/2001/XMLSchema#string

Ece Tek

http://www.w3.org/2001/XMLSchema#string

Lisa M Fucito

http://www.w3.org/2001/XMLSchema#string

Ran Wu

http://www.w3.org/2001/XMLSchema#string

Stephanie S O'Malley

http://www.w3.org/2001/XMLSchema#string

P2860

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.

Topiramate for treating alcohol dependence: a randomized controlled trial.

Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.

Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country Survey.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.

Varenicline reduces alcohol self-administration in heavy-drinking smokers

Quitting smoking and change in alcohol consumption in the International Tobacco Control (ITC) Four Country Survey.

P2888

s00213-010-2160-9

P304

655-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-010-2160-9

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

215

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227035154

http://www.w3.org/2001/XMLSchema#string

P698

21221531

http://www.w3.org/2001/XMLSchema#string

P932

3645986

http://www.w3.org/2001/XMLSchema#string